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Background Respiratory syncytial virus (RSV) is an important
pathogen in lower respiratory tract infections (LRTI) in infants, but
there are limited data concerning patients with underlying
conditions and children older than 2 years of age.
Methods We have designed a prospective observational
multicenter national study performed in 26 Spanish hospitals
(December 2011–March 2012). Investigational cases were defined as
children with underlying chronic diseases and were compared with a
group of previously healthy children (proportion 1:2). Clinical data
were compared between the groups.
Results A total of 1763 children hospitalized due to RSV infection
during the inclusion period were analyzed. Of them, 225 cases and
460 healthy children were enrolled in the study. Underlying diseases
observed were respiratory (64%), cardiovascular (25%), and
neurologic (12%), as well as chromosomal abnormalities (75%),
immunodeficiencies (67%), and inborn errors of metabolism
(35%). Cases were statistically older than previously healthy
children (average age: 163 versus 55 months). Cases experienced
hypoxemia more frequently (P < 0001), but patients with
respiratory diseases required oxygen therapy more often (OR: 299;
95% CI: 103–865). Mechanical ventilation was used more in
patients with cardiac diseases (OR: 30; 95% CI: 107–844) and in
those with inborn errors of metabolism (OR: 1227; 95% CI: 211–
7147). This subgroup showed a higher risk of admission to the
PICU (OR: 67, 95% CI: 118–3804). Diagnosis of pneumonia was
more frequently found in cases (182% versus 93%; P < 001).
Conclusions A significant percentage of children with RSV
infection have underlying diseases and the illness severity is higher
than in healthy children.
Keywords Children, hospitalization, respiratory syncytial virus,
special populations.
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Introduction
Respiratory syncytial virus (RSV) is an important pathogen
in lower respiratory tract infections (LRTI) in infants. By the
age of 2 years, more than 90% of children have already
experienced at least one RSV infection and 05–2% have
required hospitalization.1–3 Morbidity and mortality associ-
ated with RSV infections are higher in preterm infants,
especially in those with chronic pulmonary disease and in
young children with hemodynamically significant congenital
heart diseases. For both groups of patients, specific programs
regarding prophylaxis with monoclonal antibodies have been
developed.4,5 Very young infants (under 1 month of age) also
need intensive care treatment more frequently during the
RSV epidemic season.6
Respiratory syncytial virus infection is well characterized in
children younger than 2 years of age, but little is known in older
children. We also have limited data concerning other groups of
children with underlying conditions or chronic diseases. Chil-
drenwith neuromuscular diseases and chronic lung diseases, for
example, have been proven to have a higher risk of morbidity
and mortality due to RSV infection,7–9 and Mori et al.10 have
described more severe RSV disease in immunocompromised
children as compared to immunocompetent ones in Japan.
We have carried out a prospective multicenter observa-
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percentage of children having underlying diseases among the
total number of hospitalized patients under 5 years of age
with RSV infection. We compared the clinical characteristics
of two groups of patients, those “with” versus “without”
underlying diseases. As far as we know, this is the first
national prospective study of the epidemiology of RSV
infection in children under the age of 5 years in Spain.
Patients and methods
This is a national, prospective, multicenter, study performed
in 28 pediatric hospitals proportionally representative of all
Spanish communities. Recorded data in two hospitals did
not follow the study protocol, and finally 26 hospitals were
included. The study protocol was first approved by the Ethics
Committee of the Carlos Haya Hospital (Malaga) and then
by each participating hospital ethics committee.
Clinical assessment
The population studied included children younger than
5 years of age with confirmed RSV respiratory tract infection
who were admitted to participating hospitals between
December 2011 and March 2012. For each enrolled patient,
informed consent was obtained from the parents or legal
guardians. All patients were evaluated by an attending
physician. We compared children with underlying chronic
diseases (defined in Table 1) with children without any
underlying chronic diseases. For each child enrolled with
previous diseases as a case during the study period, the next
two children hospitalized due to RSV infection without
underlying chronic diseases were included. In order to
guarantee a geographic representation, recruitment was not
competitive. In each hospital, a maximum of 12 cases could
be included in the study. A total of 1763 children with
confirmed RSV infection were admitted to the 26 partici-
pating hospitals, and 264 children with underlying diseases
were considered as investigational cases (150%). A total of
232 cases and 464 previously healthy children accepted to
participate and were enrolled in the study. Of those enrolled,
four healthy children and six cases were excluded because
data were incomplete and one case because the child was
older than 5 years of age. Eventually, 225 cases and 460
previously healthy children were analyzed.
During the hospital stay, and as part of the study, a
physician filled out a study questionnaire with the following
variables: age, sex, clinical diagnosis, history of prematurity
and underlying chronic diseases, requirement for oxygen
therapy as determined by transcutaneous oxygen saturation,
fever (axillary temperature >38°C), presence of infiltrate/
atelectasis on chest radiography, administration of antibiotic
therapy, fluids or enteral feeding, duration of hospital stay,
intensive care admission, and non-invasive or mechanical
ventilation. Clinical definitions in the protocol were as
follows: upper respiratory tract infection (URTI), diagnosed
in patients with rhinorrhea and/or cough, no signs of
wheezing, dyspnea, rales, or bronchodilator use, with or
without fever. Asthma was diagnosed on the basis of the
National Asthma Education and Prevention Program guide-
lines. All other episodes of acute expiratory wheezing were
considered to be recurrent wheezing. Acute expiratory
wheezing was considered to be bronchiolitis when it occurred
for the first time in children aged <2 years. Laryngotrache-
obronchitis was associated with increased effort on inspira-
tion and wheezing, and laryngitis with increased effort on
inspiration without wheezing. Cases with both focal infil-
trates and consolidation on chest X-rays were, in the absence
of wheezing, classified as pneumonia. Respiratory distress was
Table 1. Case group: Underlying diseases by subgroups
Underlying diseases N (%)
Respiratory diseases 145 (644)
Asthma (3 or more episodes of recurrent




Malformations of the respiratory system 5
Others (tracheostomy, diaphragmatic paralysis) 11
Cardiovascular diseases 56 (249)
Congenital non-cyanotic cardiac defects 43










Others (stroke, leucomalacia) 5










Organ transplant recipient 2
Others (thalassemia major,
sickle cell disease, cyclic neutropenia)
6





Others (malnutrition and digestive disorders) 6 (27)
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considered as difficulty breathing as demonstrated in a child
with accessory respiratory muscle use, tachypnea, supraster-
nal or subcostal retractions.
Specimens from patients were collected using nasopha-
ryngeal aspirates and were taken from each subject upon
admission. Specimens were processed immediately using an
enzyme-linked immunosorbent assay.
Statistical analysis
The estimate of the proportion of children hospitalized with
RSV who had an underlying disease was measured by relative
frequency (percentage) with a confidence interval of 95%.
Descriptive statistics were measured by absolute frequencies
and percentages for qualitative data. For quantitative data,
the mean and standard deviation (SD) or median and upper
and lower quartiles were used. The comparison between the
two groups (i.e., those with versus without chronic under-
lying diseases) for qualitative variables was made using chi-
square test and Fisher’s exact test, with at least one expected
frequency of <5. The comparison of quantitative nonpara-
metric variables was performed using Student’s t-test or
Mann–Whitney U-test when two groups were compared and
analysis of variance (ANOVA) or Kruskal–Wallis test when
more than two independent groups were compared. P-values
<005 were considered statistically significant. Assessment of
risk factors associated with more severe RSV disease was
made using multivariate logistic regression for binary
outcome variables and multiple linear regression models
for continuous outcome variables. All results were calculated
both non-adjusted and adjusted by age.
Results
Demographic and epidemiological data
In total, 685 patients were analyzed: 225 patients (329%)
were included in the case group (underlying diseases) and
460 patients (671%) in the group of previously healthy
children. The final ratio of cases versus healthy children was
204.
Cases were statistically significantly older (average age:
163 months; range: 03–59 months) than healthy children
(55 months; 03–46 months) (P < 0001) (Table 2). By
underlying condition subgroup, immunocompromised
patients were on average the oldest (212 months) and
metabolic patients the youngest (52 months). Therefore, all
results were adjusted by age.
More males were enrolled in the study than females (ratio:
158) both in cases (147) and in previously healthy children
(164), but the difference was not statistically significant
(P = 056).
A larger percentage of children with underlying diseases
attended day care or school than previously healthy children
(676% versus 148%, P < 0001). No differences were
observed between the groups when variables such as number
of siblings (P = 014) and smokers in the home (P = 038)
were analyzed.
The percentage of preterm infants observed in the case
group (n = 67/225, 432%) was larger than in the group of
previously healthy children (n = 58/460, 163%)
(P < 0001). In terms of weeks of gestation, preterms in
the case group were younger (median: 308 weeks) than in
the previously healthy children (median: 344 weeks)
(P < 0001).
A history of administration of palivizumab was more
frequent in the case group (167% versus 18%, P < 0001)
(Table 2).
Underlying conditions in case group
During the study period (from the first case to the last
patient included in each center), 1763 children under 5 years
of age were admitted because of RSV infection in 26 Spanish
hospitals. Of them, 264 (150%) were children with under-
lying conditions and therefore potential candidates to be
included in the study. This proportion ranged between 34%
Table 2. Epidemiological and clinical features
Case group (underlying diseases) Previously healthy group P value
Median age (IQR Q1-Q3) (months) 1249 (526–2321) 296 (132–680) <0001
Prematurity (≤37 weeks) 67/155 (432%) 63/386 (163%) <0001
Palivizumab (previous administration) 30/179 (167%) 8/425 (18%) <0001
Duration of fever (mean) (days) 289 224 <0001
Poor feeding 38/225 (169%) 81/460 (17%) n.s.
Respiratory distress 182/225 (809%) 354/460 (770%) n.s.
Hypoxemia at admission (O2 Sat <92%) 114/225 (507%) 151/460 (328%) <0001
Chest X-ray 172/225 (764%) 243/460 (528%) <0001
Pathologic chest X-ray 137/172 (796%) 190/243 (782%) n.s.
IQR, interquartile range; Q1, quartile 1; Q3, quartile 3; n.s., non-significant.
Hospitalizations due to RSV infection in children
ª 2014 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. 211
and 333% among centers. We calculated a weighted
percentage, quantifying for the heterogeneity between cen-
ters, to be 152% (95% CI: 1251–1811%). This percentage
was calculated using a random effect model.
In the case group, 225 patients were included. Of them,
183 patients (813%) had at least one underlying disease, 35
(156%) two diseases, and 7 (31%) three diseases.
The distribution by underlying conditions in the case
group is shown in Table 1. Children with respiratory diseases
formed the predominant group (145 patients, 644%),
followed by those with cardiovascular diseases, neurologic
diseases, chromosomal abnormalities, immunocompromised
patients, and children with inborn errors of metabolism.
The predominant underlying respiratory disease was
asthma (=3 or more episodes of recurrent wheezing diagnosed
by a physician), which included 100 cases, that is, 690% of the
total number of respiratory patients. Most of these patients
suffered from an episodic form of asthma (48 cases, 480%).
Clinical features on admission
The differences between cases and previously healthy
children are shown in Table 2. Patients with underlying
conditions experienced fever more frequently, which was
higher in degree and lasted longer than the other group.
Respiratory distress was similar between the groups
(P = 028), but cases showed hypoxemia (oxygen saturation
<92% on room air) more frequently (507%) than previously
healthy children (328%) (P < 0001).
Thoracic radiographs were performed more often among
cases with underlying diseases (764% versus 528%;
P < 0001), but no differences were observed in terms of
pathological findings (P = 081).
Therapeutic measures regarded as severity markers
Some markers of hospitalization and therapeutic measures
were associated with a higher degree of severity in the case
group. These items are shown in Table 3. Use of an
intravenous line, antibiotics, and enteral nutrition by naso-
gastric tube was significantly more frequent in the case group
(P < 001). Antibiotic therapy was more frequently used in
immunocompromised patients (OR: 437; 95% CI: 113–
1695).
Patients with underlying conditions required oxygen
therapy more frequently and for longer periods of time than
children without underlying diseases, even when the need for
high-flow oxygen therapy was analyzed independently. On
the other hand, there was no association with the use of non-
invasive ventilation (Table 3). The main significant markers
of severity were calculated both non-adjusted and adjusted
by age and are reflected in Table 4. Patients with two or more
underlying diseases were at a higher risk of requiring oxygen
(OR: 37, 95% CI: 108–127, P = 003) and fluid therapy
(OR: 21, 95% CI; 108–44, P = 003) than children with
only one comorbidity (data adjusted by age).
However, when comparisons of cases versus previously
healthy children were made according to subgroups of
pathologies, the probability of using oxygen therapy was
significantly higher for the cases only in patients with
underlying respiratory diseases (OR: 299; 95% CI: 103–
865) (Table 5).
Mechanical ventilation was used in a significantly greater
proportion of patients with cardiac diseases (OR: 30; 95%
CI: 107–844) and in those with inborn errors of metabolism
(OR: 1227; 95% CI: 211–7147). Patients with inborn errors
of metabolism showed a higher risk of admission to the
Table 3. Severity markers of therapeutic measures in both groups
Case group (underlying diseases) Previously healthy group P value
Oxygen therapy 184/225 (818%) 334/458 (729%) <005
Median duration of oxygen therapy (IQR Q1-Q3) (days) 30 (10–50) 20 (00–30) <0001
High-flow oxygen therapy 32/225 (142%) 33/460 (72%) <001
Median length of high-flow oxygen therapy (IQR Q1-Q3) (days) 35 (20–575) 20 (175–30) <005
Non-invasive ventilation 24/225 (107%) 36/460 (78%) n.s.
Median length of non-invasive ventilation (IQR Q1-Q3) (days) 40 (20–75) 20 (10–40) 0057
Mechanical ventilation 14/225 (62%) 8/460 (17%) <001
Median length of mechanical ventilation (IQR Q1-Q3) (days) 70 (45–132) 60 (57–60) n.s.
Venous line 114/225 (507%) 160/452 (354%) <0001
Nasogastric tube feeding 41/212 (193%) 42/419 (100%) <001
Antibiotic therapy 111/225 (493%) 136/452 (301%) <0001
Length of stay (mean, days  SD) 803 (13) 535 (03) <001
Admitted to PICU since first day of hospitalization 13/225 (58%) 22/460 (48%) n.s.
Admitted to PICU during hospitalization 42/225 (186%) 52/454 (115%) <005
Median length of stay in PICU (IQR Q1-Q3) (days) 50 (30–100) 40 (20–50) <005
PICU, pediatric intensive care unit; SD, standard deviation; n.s., non-significant; IQR, interquartile range.
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pediatric intensive care unit (PICU) than the other sub-
groups (OR: 67, 95% CI: 118–3804) (Table 5).
An additional subanalysis of the group of patients with a
history of recurrent wheezing was performed and adjusted by
age. This group of children required oxygen therapy (OR:
177, 95% CI: 102–307, P = 004), nasogastric tube feeding
(OR: 299, 95% CI: 149–599, P = 0002), and mechanical
ventilation (OR: 268, 95% CI: 122–588, P = 001) more
frequently than previously healthy children. Nevertheless,
when we compared the other patients with underlying
diseases to the recurrent wheezing group, PICU admission
(OR: 25, 95% CI: 126–502, P = 0009), mechanical ven-
tilation (OR: 238, 95% CI: 106–531, P = 003), and
nasogastric tube feeding (OR: 239, 95% CI: 118–483,
P = 001) were more frequent in patients with other
underlying diseases.
Final diagnosis and outcome
A final diagnosis of pneumonia was more frequent in cases
than in previously healthy children (182% versus 93%;
P < 001). Other complications observed, all in the case
group, were pleural effusion (3/225; 13%) and pneumo-
thorax 1/225 (08%).
There were two deaths (2/225, 09%), both in the case
group. One patient was a 4-month-old infant with severe
combined immunodeficiency and hepatoblastoma with
Table 4. Markers of severity in patients with underlying diseases compared with previously healthy children adjusted by age
Raw data Adjusted by age data
OR 95% CI P OR 95% CI P
PICU admission 177 (114–276), 00145 258 (156–425) 00002
Fever 146 (105–203) 00292 09 (062–132) 06023
Oxygen requirement 167 (112–248) 00145 166 (106–258) 00262
Mechanical ventilation. 181 (109–3) 00285 364 (205–644) 00001
Venous line 187 (135–259) 00002 186 (129–268) 00009
Antibiotic treatment 226 (163–315) <00001 173 (12–251) 00037
Nasogastric tube feeding 215 (135–343) 00017 326 (193–551) 00001
Days of hospitalization 268 (134–403) 00001 369 (255–483) 00001
Stay at PICU 4 (128–752) 00069 487 (18–794) 00026
OR, odds ratio; CI, confidence interval; PICU, pediatric intensive care unit.
Table 5. Markers of severity in patients with underlying disease subgroups compared with previously healthy children (odds ratio and confidence
interval)
Oxygen therapy Mechanical ventilation PICU admission




































PICU, pediatric intensive care unit.
Results in boldface are statistically significant.
*P < 005, **P < 005, ***P < 001, †P < 005.
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metastasis. The other one was a 2-year 8-month-old child
with a terminal neuroblastoma. Both of them developed
severe respiratory distress syndrome.
Discussion
We present a large prospective, multicenter study of children
under 5 years of age hospitalized due to RSV infection in
Spain. This is the first epidemiological study conducted in
our country in this population. The main objective of the
study was to identify and characterize risk groups or
children with underlying diseases who are hospitalized for
RSV infection in our community. Our data show that
approximately 15% of hospitalized children have underlying
diseases, especially respiratory, cardiac, and neurologic
diseases, but other groups, such as immunocompromised
children or those with chromosomal and metabolic diseases,
also represent a significant percentage. Children with
underlying diseases have certain markers of disease severity
at admission (Table 2). During hospitalization, they are
admitted for longer periods of time, have a higher require-
ment for oxygen therapy, and also more often require
hospitalization in intensive care units. They show a higher
percentage of complications than children without any
underlying disease.
This is a comparative study between children with
underlying diseases and previously healthy children under
5 years of age. The characteristics of the previously healthy
group show that our population is consistent with the
epidemiology of RSV infection widely known and published
in normally healthy children without underlying disease. The
average age was 55 months (median: 3 months), and the
diagnosis was bronchiolitis in 86% as is typically the
case.11–16 Pneumonia only represented 96% of the cases. A
history of prematurity (average gestational age of 34 weeks)
was seen in 163%, but only eight children (18%) had
received prophylaxis with palivizumab. Fifty-two children
(115%) were admitted to the PICU. Although young age
and incidence of prematurity could have raised the degree of
severity in this group, children with underlying diseases had a
worse outcome in most of the parameters analyzed when the
results were adjusted by age, with a regression model.
The proportion of children with underlying diseases has
been analyzed in other series. However, all studies found
were retrospective. Kristensen et al.,17 in a population cohort
study in Denmark found that 88% of all children under
2 years of age hospitalized with RSV infection had a chronic
condition. They found that chronic diseases such as immu-
nodeficiency, cerebral palsy, and other neuromuscular
diseases, hepatic disease, inborn errors of metabolism, cystic
fibrosis, chromosomal defects, and malformation syndromes
incurred a higher risk of RSV hospitalization (P < 001). Our
study shows a higher percentage of patients with underlying
diseases (15%) most likely because we included children with
a diagnosis of asthma (more than three episodes of wheezing
diagnosed by a physician). Children with respiratory diseases
comprised the most prevalent group in our series. Moreover,
the distribution of diseases in our series is similar to the data
found in the Danish cohort. Patients with inborn errors of
metabolism also showed high risk, as in the group of
Kristensen et al.17 These authors speculate that the higher
rate of admission for this last group was explained by gastric
intolerance; however, this does not appear to be the case in
our series because our hospitalized children were at high risk
of admission at PICU and mechanical ventilation risk. We
have no explanation for these results. Other groups, such as
cardiac and neurologic patients or immunodeficient
children, were similar in our cohort.
In a retrospective study conducted in Japan during two
consecutive RSV epidemic seasons, Mori et al.10 found in a
nationwide survey that 1115 children under 4 years of age
who did not meet the criteria for palivizumab therapy were
hospitalized for severe RSV infection. Children with pre-
existing diseases (n = 756) were compared with healthy
controls (n = 359). Respiratory diseases represented the
main group in the series (548%), mainly asthma (460%),
followed by chromosomal abnormalities and malformation
syndromes (172%; 75% with Down’s syndrome without
cardiopathy) and neuromuscular disorders (165%). Another
similarity with our series was the higher median age in
patients with chronic diseases (204 versus 67 months).
Sixteen patients (14%) died, eleven with underlying diseases,
mainly with chromosomal defects, neuromuscular diseases,
or immunocompromised. A risk of poor outcome from RSV
disease was approximately 1000 times higher in immuno-
compromised children than in those with respiratory disor-
ders and approximately 28–43 times higher than in patients
with other underlying conditions. They concluded that
palivizumab should be considered in other patients with
underlying conditions at risk of severe RSV infection in
whom prevention of RSV infection by standard control
measures appears to be difficult.
In a cohort study of children with severe RSV infection
conducted in England between 1999 and 2007, all the
children who died of RSV infection (n = 35) had underlying
conditions (relative risk: 236). Multiple pre-existing diseases
(RR: 438) and congenital cardiac defects (RR: 298) were
considered risk factors for death from severe RSV infection.8
Recently, additional data from England have been reported.
Pockett et al.18 found that children under 5 years of age with
chronic diseases such as cystic fibrosis, insulin-dependent
diabetes mellitus, cancer, or epilepsy hospitalized with RSV or
rotavirus infection in comparison with healthy controls were
older (11 years, SD: 13 years), had greater length of hospital
stay (99 days, SD: 199), and incurred a higher cost (£3477,
SD: £7765) than healthy controls (age: 02 years, SD: 05,
Moreno-Perez et al.
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P < 0001; length of stay 19 days, SD: 31, P < 0001; cost
£595, SD: £727, P < 0001). Cost for cases was six times
higher than in healthy controls (P < 0001).
We found that 124% of our cases was represented by a
group of patients with neurologic diseases. In a prospective
multicentric German study (1999–2005), patients hospital-
ized with RSV infection and neuromuscular disease showed a
greater risk of requiring mechanical ventilation (96% versus
19%), with a statistically significant higher degree of
mortality compared to controls (55% versus 02%).7
In a prospective Spanish study, Down’s syndrome was
identified as an independent risk factor of RSV hospitaliza-
tion (relative risk: 26; 95% CI: 14–47).19 In a study
conducted in Colorado (USA), children with Down’s
syndrome were at a higher risk of being hospitalized with
RSV LRTI even in the absence of coexisting risk factors (OR:
35; 95% CI: 310–412).20
We have recognized two main potential limitations in our
study. First, this study was conducted in a single epidemi-
ological season; therefore, the variability between seasons
could not be determined, either with higher or lower severity
of infections occurring between years. However, the results
for healthy children are absolutely comparable to studies
conducted in our area during several epidemiological
seasons.11 The second observed limitation is that previously
healthy children had an average age significantly lower than
the case group, in such a way that the two groups may not
be comparable. However, healthy children hospitalized
because of RSV infection tended to be young, and the
severity was even higher in the youngest children, giving
more value to data regarding severity that we found in the
case group, where children were older. And the most
important parameters of severity were significantly worse in
children with underlying diseases when raw data were
adjusted by age.
In summary, we know that a significant percentage of
children with RSV infection have underlying diseases. The
duration of hospitalization and the severity of the illness were
both higher in these patients than in healthy children. In our
series, patients with respiratory diseases had an increased risk
of oxygen therapy requirement; children with heart diseases
had a higher risk of requiring mechanical ventilation, and
children with inborn errors of metabolism had a very high
risk of admission to PICU and requiring mechanical
ventilation. Awareness and strategies that decrease the risk
and burden of RSV infections in these groups of children
may be beneficial in addressing the respiratory health among
this vulnerable population. The potential role of palivizumab
in some special populations that do not meet current criteria
of the guidelines for the prevention of severe RSV infection is
a present subject of debate. Larger prospective studies are
needed to identify underlying conditions with higher risk of
severe RSV infection.21
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